Apellis Pharmaceuticals

Apellis Pharmaceuticals is a biopharma company harnessing bold science, creativity, and compassion to bring life-changing therapies to patients worldwide. Founded in 2008, Apellis focuses on developing innovative treatments for various debilitating diseases by targeting complement, a key component of the immune system. At the core of their efforts is C3, the sole target in the complement cascade addressing all three disease-driving pathways. By targeting C3, the company has broad platform potential to address diseases with limited treatment options, spanning ophthalmology, nephrology, hematology, and neurology. Their commitment to community engagement is evident in their community guidelines (Community guidelines). Apellis Pharmaceuticals secured a Post-IPO Equity investment on January 1, 2020, with the backing of Solasta Ventures. This investment underscores the confidence in the company's innovative approach and potential to deliver meaningful advancements in patient care.